Can aspirin help tackle some cancers?
Low-dose aspirin may improve survival odds for patients battling head/neck and lung cancer, two new studies suggest.
Sep 23, 2019
0
2
Low-dose aspirin may improve survival odds for patients battling head/neck and lung cancer, two new studies suggest.
Sep 23, 2019
0
2
Researchers from several major U.S. universities and ITMO University in Russia have identified a number of new driver mutations in lung cancer cells that may be responsive to genomically targeted therapies and to immunotherapy.
May 10, 2016
0
29
A Melbourne study is set to improve treatment options for patients with the second most common type of lung cancer, lung squamous cell carcinoma, a disease for which new anti-cancer drugs are urgently needed.
Jun 13, 2017
0
2
A chromatin-regulating enzyme has been shown by in-depth interdisciplinary investigations to be a key driver of a common type of lung cancer. Drugs that target the enzyme could improve treatment and survival rates for this ...
Mar 15, 2021
0
35
Knowing what type of lung cancer a patient has is critical to determine which drug will work best and which therapies are safest in the era of personalized medicine. Key to making that judgment is an adequate tumor specimen ...
Jul 16, 2013
0
0
Using the OncoArray genotyping platform developed by multiple cancer consortia, a recent large aggregated genomewide association study identifies new susceptibility loci for lung cancer, the leading cause of cancer mortality ...
Jun 13, 2017
0
1
A prospective study by researchers at Brigham and Women's Hospital (BWH) observed an association between risk of second primary cancer and history of non-melanoma skin cancer in white men and women.
Apr 23, 2013
0
0
The lung transcription factor Nkx2-1 is an important gene regulating lung formation and normal respiratory functions after birth. Alterations in the expression of this transcription factor can lead to diseases such as lung ...
Mar 2, 2015
0
4
(HealthDay)—Two new drugs, Tafinlar (dabrafenib) and Mekinist (trametinib), have been approved by the U.S. Food and Drug Administration to treat advanced melanoma, the most dangerous form of skin cancer.
May 29, 2013
0
0
Researchers at Okayama University describe in Oncotarget an approach for suppressing the expression of the SOX2 protein, an oncogene associated with both lung and esophageal cancer. The procedure, based on the targeted delivery ...
Nov 30, 2017
0
1